Aminosalicylic acid indications and usage: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Aminosalicylic acid}} | {{Aminosalicylic acid}} | ||
{{CMG}} ; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
==Indications and Usage== | ==Indications and Usage== |
Latest revision as of 22:08, 25 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Indications and Usage
PASER is indicated for the treatment of tuberculosis in combination with other active agents. It is most commonly used in patients with Multi-drug Resistant TB (MDR-TB) or in situations when therapy with isoniazid and rifampin is not possible due to a combination of resistance and/or intolerance. When PASER is added to the treatment regimen in patients proven or suspected drug resistance, it should be accompanied by at least one and preferably two other new agents to which the patient's organism is known or expected to be susceptible.[1]
References
Adapted from the FDA Package Insert.